Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2023 Filed Dec 12, 2023 00:15 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029249 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,987 Underlying: Common Stock · 2,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:15 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 1,247 | $79.02 | $98,537.94 |
DisclosureSEC source: 0001127602-23-029249 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,971 Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:15 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029249 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 23:21 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-027287 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,451 Underlying: Common Stock · 1,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 23:21 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 804 | $75.92 | $61,039.68 |
DisclosureSEC source: 0001127602-23-027287 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,111 Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 23:21 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 1,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-027287 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 21:56 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-026281 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,337 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 21:56 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Tax withholdingCommon Stock | 243 | $78.39 | $19,048.77 |
DisclosureSEC source: 0001127602-23-026281 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,762 Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 21:56 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-026281 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 20:31 UTC |
Dickinson Andrew DChief Financial Officer
|
SaleCommon Stock | 5,000 | $80.00 | $400,017.00 |
DisclosureSEC source: 0001127602-23-026065 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,003 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 24, 2023. F2 · price: Sale prices reported for the transactions reported here range from $80.00 to $80.02. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 28, 2023 Filed Sep 30, 2023 00:09 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 31.4564 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-024892 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194.7161 Underlying: Common Stock · 31.4564 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 22:50 UTC |
Parsey MerdadChief Medical Officer
|
SaleCommon Stock | 1,501 | $76.99 | $115,561.99 |
DisclosureSEC source: 0001127602-23-024115 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,130 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 30, 2022. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:11 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023977 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,239 Underlying: Common Stock · 7,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:11 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 3,366 | $76.00 | $255,816.00 |
DisclosureSEC source: 0001127602-23-023977 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,685 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:11 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 7,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023977 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:19 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023979 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,754 Underlying: Common Stock · 2,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:19 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 1,278 | $76.00 | $97,128.00 |
DisclosureSEC source: 0001127602-23-023979 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,631 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:19 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023979 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:37 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionRestricted Stock Unit · Derivative | 519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023981 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,038 Underlying: Common Stock · 519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:37 UTC |
Patterson SandraSVP, Controllership
|
Tax withholdingCommon Stock | 149 | $76.00 | $11,324.00 |
DisclosureSEC source: 0001127602-23-023981 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,124 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:37 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionCommon Stock | 519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023981 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:40 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023983 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,363 Underlying: Common Stock · 2,619 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:40 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,203 | $76.00 | $91,428.00 |
DisclosureSEC source: 0001127602-23-023983 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,003 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:40 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 2,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023983 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023985 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,717 Underlying: Common Stock · 2,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 1,256 | $76.00 | $95,456.00 |
DisclosureSEC source: 0001127602-23-023985 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,488 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023985 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022375 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,557 Underlying: Common Stock · 4,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC |
Patterson SandraSVP, Controllership
|
Tax withholdingCommon Stock | 1,306 | $80.00 | $104,480.00 |
DisclosureSEC source: 0001127602-23-022375 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,754 Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionCommon Stock | 4,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022375 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 20:53 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-021338 · form4.xml · derivative · entry 5 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,851 Underlying: Common Stock · 2,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 20:53 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-021338 · form4.xml · derivative · entry 4 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,909 Underlying: Common Stock · 8,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 20:53 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 2,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-021338 · form4.xml · nonDerivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 20:53 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Tax withholdingCommon Stock | 4,174 | $77.23 | $322,358.02 |
DisclosureSEC source: 0001127602-23-021338 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,433 Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 20:53 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 8,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-021338 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 22:15 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-021245 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,447 Underlying: Common Stock · 7,505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 22:15 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 3,174 | $77.66 | $246,492.84 |
DisclosureSEC source: 0001127602-23-021245 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,326 Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 22:15 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 7,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-021245 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 21:30 UTC |
Dickinson Andrew DChief Financial Officer
|
SaleCommon Stock | 5,000 | $80.00 | $400,000.00 |
DisclosureSEC source: 0001127602-23-021162 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,587 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 24, 2023. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 19:54 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 30.9073 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019607 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,163.2596 Underlying: Common Stock · 30.9073 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 21:48 UTC |
Parsey MerdadChief Medical Officer
|
SaleCommon Stock | 1,485 | $76.90 | $114,196.50 |
DisclosureSEC source: 0001127602-23-018727 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,402 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 30, 2022. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:39 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018579 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,952 Underlying: Common Stock · 2,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:39 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 1,272 | $78.12 | $99,368.64 |
DisclosureSEC source: 0001127602-23-018579 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,995 Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:39 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018579 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:37 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018577 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,982 Underlying: Common Stock · 2,618 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:37 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,219 | $78.12 | $95,228.28 |
DisclosureSEC source: 0001127602-23-018577 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,701 Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:37 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 2,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018577 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:42 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018583 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,587 Underlying: Common Stock · 7,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:42 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 3,409 | $78.12 | $266,311.08 |
DisclosureSEC source: 0001127602-23-018583 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,125 Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:42 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 7,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018583 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.